Latin America Pharmaceutical Drug Delivery Market

The Latin America pharmaceutical drug delivery market is projected to reach USD 102.1 billion by 2031 from USD 75.3 billion in 2026, at a CAGR of 6.3% during the forecast period. The Latin America pharmaceutical drug delivery market is experiencing steady growth. A significant factor contributing to this expansion is the increasing use of biologics, biosimilars, cell & gene therapies, and advanced precision medicines by major healthcare systems in Brazil, Mexico, Argentina, Colombia, and Chile. These innovative treatments typically require drug delivery systems that are not only reliable and efficient but also enhance treatment accuracy, improve bioavailability, and ensure greater patient safety. Additionally, the rising prevalence of chronic and lifestyle diseases, such as cancer, diabetes, respiratory disorders, and autoimmune diseases, in the region is driving the demand for new drug delivery solutions. This includes long-acting injectables, self-injection systems, transdermal patches, inhalation devices, and subcutaneous drug delivery platforms.

Technological advancements in prefilled syringes, advanced injectors, wearable injectors, inhalers, and patient-friendly delivery devices are creating new growth opportunities for pharmaceutical companies in the region. Additionally, limitations in hospital capacities have led many patients to seek home-based treatments and self-administration, making these innovative delivery methods increasingly important. Furthermore, investments in pharmaceutical research and development, the growth of biologics pipelines, and regulatory support for drug-device combinations from agencies such as ANVISA (Brazil), COFEPRIS (Mexico), ANMAT (Argentina), and INVIMA (Colombia) are driving market expansion. Together, these factors, along with the ongoing development of healthcare infrastructure in the region's emerging markets, are driving robust market growth.

To know about the assumptions considered for the study download the pdf brochure

Currently, some of the major players active in the Latin America pharmaceutical drug delivery market are Pfizer Inc. (US), Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Sanofi (France), AstraZeneca (UK), GSK plc (UK), Eurofarma (Brazil), Bayer AG (Germany), EMS (Brazil), and BD (US).

• In November 2025, EMS acquired Fresenius Kabi’s injectable drug operations in Goiás (Brazil), including a manufacturing plant, R&D capabilities, and distribution infrastructure, to strengthen its presence in the hospital segment. The deal marks EMS’s re-entry into injectables, adds key products such as antibiotics and corticosteroids, and is expected to boost revenue by ~USD 30 million, with further growth potential.
• In October 2023, Eurofarma, the first multinational pharmaceutical company with 100% Brazilian capital, completed the acquisition of Genfar, Sanofi’s generics operation headquartered in Colombia, along with its affiliates in Ecuador and Peru. The acquisition was finalized on September 29, 2023.

Pfizer Inc. (US)

Pfizer Inc. holds a strong position in the Latin America pharmaceutical drug delivery market, supported by its extensive commercialization rights and broad international footprint across North and Latin America. The company maintains commercialization rights for multiple innovative therapies across the region, enabling direct participation in LATAM markets and strengthening its presence in hospital and specialty care segments. The company benefits from its advanced therapeutics, mRNA technology, and drug-device combinations. Pfizer's innovative work in nucleic acid-based technologies, including lipid nanoparticle (LNP) systems used in mRNA vaccines and new gene therapy candidates, has established it as a leader in next-generation drug delivery. Additionally, Pfizer manufactures a wide range of medicines for oral, injectable, inhalation, and sustained-release applications, ensuring therapeutic precision and patient adherence in the treatment of immunology, oncology, cardiovascular, and infectious diseases.

Pfizer generates a significant share of its revenues from international markets (over 50% of total revenue), with operations spanning emerging markets, including Latin America, indicating strong geographic diversification and reliance on regions such as LATAM for growth. Moreover, Pfizer is continually developing digital health integration, self-administration technologies, and improved delivery methods for complex biologics. Additionally, Pfizer’s global portfolio spanning vaccines, oncology, anti-infectives, and specialty therapeutics aligns with the disease burden in LATAM and drives demand for injectable and advanced drug delivery systems, particularly in institutional care settings. These advancements help maintain Pfizer's status as one of the most dominant and progressive companies in the Latin America pharmaceutical drug delivery market.

F. Hoffmann-La Roche Ltd. (Switzerland)

F. Hoffmann-La Roche Ltd. is a key player in the Latin America pharmaceutical drug delivery market, driven by its focus on innovative pharmaceuticals and biologics, particularly in oncology, immunology, and specialty care. F. Hoffmann-La Roche is a well-established, research-driven healthcare company that operates through two main business segments: Pharmaceuticals (Roche Pharmaceuticals) and Diagnostics (Roche Diagnostics). The Pharmaceuticals segment includes a range of drug-delivery products. Roche offers a broad range of products across several therapeutic areas, including oncology, immunology, infectious diseases, ophthalmology, hemophilia A, neuroscience, and others. The company operates in regions such as the Asia Pacific, North America, Latin America, Europe, the Middle East, and Africa. Roche operates through a globally integrated pharmaceutical and diagnostics business model, enabling strong penetration across international markets, including Latin America, where demand for biologics and specialty medicines is increasing. The company’s emphasis on innovation and personalized healthcare supports the development of patient-centric drug delivery approaches, including subcutaneous and hospital-administered therapies, which are critical in LATAM markets characterized by rising chronic disease burden and increasing adoption of biologics.

Novartis AG (Switzerland)

Novartis AG is a leading player in the Latin America pharmaceutical drug delivery market, supported by its measurable revenue contribution from the region. In 2024, Novartis reported USD 3.6 billion in net sales from Canada and Latin America, accounting for approximately 7% of its total global revenue (USD 50.3 billion), indicating a meaningful commercial footprint in the region. The company boasts a strong portfolio of pharmaceutical drug delivery products and is recognized for its brand strength. Novartis operates in multiple therapeutic areas, including Cardiovascular, Renal and Metabolic, Immunology, Neuroscience, and Oncology. Additionally, Novartis continues to prioritize expansion in emerging markets as a core growth strategy, supported by strong commercial infrastructure and access to public healthcare systems across the region. Its increasing focus on biologics and advanced therapies further strengthens its positioning in LATAM, where demand for complex drug delivery systems is rising rapidly in hospital and specialty care settings.

Sanofi (France)

Sanofi is a key participant in the Latin America pharmaceutical drug delivery market, supported by its broad presence across emerging markets and strong positioning in vaccines, specialty care, and chronic disease management. Sanofi manufactures and sells healthcare products. It operates through two business segments: Biopharma and Consumer Healthcare. The Biopharma operating segment comprises commercial operations, research, development, and production activities relating to Specialty Care, General Medicines, and Vaccines franchises. The company offers various products for diabetes, rare diseases, multiple sclerosis, oncology, thrombosis & cardiovascular disease prevention, nephrology, and biosurgery. Through the Vaccines segment, the company offers vaccines in five major areas: pediatric, influenza, adult & adolescent boosters, meningitis, and travel & endemic. It offers pharmaceutical drug-delivery products across both segments. Sanofi has established a strong footprint in Latin America, particularly in Brazil and Mexico, supported by local manufacturing, commercial operations, and public health partnerships, especially in the vaccines segment.

AstraZeneca (UK)

AstraZeneca plc is an innovative pharmaceutical company focused on oncology, cardiovascular, renal & metabolism, and respiratory diseases. AstraZeneca plc is a prominent player in the Latin America pharmaceutical drug delivery market. The company is involved in discovering, developing, and manufacturing an extensive portfolio of prescription medicines used in specialty and primary care. The company operates in a single business segment. However, based on therapy areas, it is segmented into oncology, rare diseases, and biopharmaceuticals. Geographically, the company operates in more than 160 countries across North America, Europe, the Middle East, Africa, and the Asia Pacific. The company also operates through local subsidiaries such as AstraZeneca do Brasil Ltda. and AstraZeneca S.A. de C.V. (Mexico). Additionally, AstraZeneca continues to expand access to innovative medicines in Latin America through localized partnerships, supply chain investments, and participation in large-scale public health programs, reinforcing its positioning in markets with high biologics uptake. Its strong pipeline in biologics and specialty care further strengthens its role in driving demand for complex drug delivery systems across the region.

Market Ranking

The leading pharmaceutical drug delivery companies in the Latin America region include Pfizer Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Sanofi (France), and AstraZeneca (UK).

Pfizer is actively strengthening its position in Latin America with a diverse portfolio of injectable therapies, vaccines, and self-administration formats that support large public health programs throughout the region. F. Hoffmann-La Roche Ltd. maintains its leadership by increasing the use of injectable and subcutaneous biologics, which enhance access to oncology treatments and chronic disease management. Novartis AG is continually expanding its activities with autoinjector-based biologics, long-acting treatments, and patient-friendly delivery systems that enable home-based care. Sanofi holds a significant market share, primarily driven by its insulin delivery pens, vaccines, and biologic therapies that play a crucial role in chronic disease control in the region. AstraZeneca is positioning itself for future growth in the Latin America pharmaceutical drug delivery market by pursuing initiatives across its respiratory inhaler platforms, injectable biologics, and an expanding portfolio of targeted therapies that improve treatment outcomes.

The accelerated growth of long-acting injectables, advanced self-injection systems, inhalation devices, controlled-release formulations, and next-generation delivery platforms is driving the commercial momentum of these leading companies in the Latin America pharmaceutical drug delivery market.

Related Reports:

Latin America Pharmaceutical Drug Delivery Market by Route of Administration [Injectable (Prefilled Syringe, Self Injection Devices), Oral (Tablet, Capsule, Liquid), Topical, Buccal, Nasal, Rectal], Application (Cancer, Diabetes, CVD) - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com